19
December 2024
Aptamer
Group plc
("Aptamer", the "Company" or the "Group")
Notification of dealings by a director/PDMR
Aptamer Group plc (AIM: APTA), the developer of
novel Optimer® binders to enable innovation in
the life sciences industry, today announces that David Bunka, Chief
Scientific Officer, on 19 December 2024 purchased 1,317,870
ordinary shares of £0.001 each ("Ordinary Shares") in the Company
at a price of 0.3794 pence per Ordinary Share.
Following this transaction, David
Bunka's total beneficial interest in the Company is 19,842,070
Ordinary Shares, representing approximately 1.00% of the Company's
issued share capital.
The following disclosures are made in
accordance with the requirements of the UK Market Abuse Regulation
and provide detail in relation to the purchase of ordinary shares
by directors and other PDMRs in the Company.
NOTIFICATIONS AND PUBLIC DISCLOSURE
OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES
AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1
|
Details of the
person discharging managerial responsibilities / person closely
associated
|
|
a)
|
Name
|
David Bunka
|
|
2
|
Reason for the
notification
|
|
a)
|
Position/status
|
Chief Scientific Officer
|
|
b)
|
Initial notification /Amendment
|
Initial notification
|
|
3
|
Details of the
issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
|
|
a)
|
Name
|
Aptamer Group plc
|
|
b)
|
LEI
|
213800Y4XGH3WJNBE686
|
|
4
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type
of instrument
|
Ordinary shares of £0.001 each
|
|
|
|
|
Identification code
|
GB00BNRRP542
|
|
|
|
|
b)
|
Nature of the transaction
|
Purchase of shares
|
|
c)
|
Price(s) and volume(s)
|
Price 0.3794p
Volume 1,317,870
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
1,317,870
|
|
- Price
|
0.3794p
|
|
|
|
|
e)
|
Date of the transaction
|
19 December 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange
|
- Ends
-
For further information, please
contact:
|
Aptamer Group plc
Arron Tolley, Chief Executive
Officer
|
+44 (0) 1904 217 404
|
|
SPARK Advisory Partners Limited -
Nominated Adviser
Andrew Emmott / Adam
Dawes
|
+44 (0) 20 3368 3550
|
|
Turner Pope Investments (TPI)
Limited - Broker
James Pope / Andrew
Thacker
|
+44 (0) 20 3657 0050
|
|
Northstar Communications Limited -
Investor Relations
Sarah Hollins
|
+44 (0) 113 730 3896
|
This announcement contains inside
information for the purposes of the UK Market Abuse
Regulation.
About Aptamer Group plc
Aptamer Group is a leading global developer of
aptamer-based ligands that help scientists remove the limits to
discovery and innovation. Leveraging a proprietary discovery and
development platform, Aptamer delivers custom affinity ligands,
supported with a complete suite of characterisation and validatory
assays that enhance the translation of its binders and optimise
scientific outcomes for customers.
Aptamer's cutting-edge technology spans
healthcare, research, personal care, and industrial processes,
delivering new affinity solutions for novel targets, advanced
diagnostics, and precision therapies. By working with industry
leaders in pharmaceutical, biotechnology, personal health,
academic, and clinical research sectors, Aptamer is accelerating
science through the custom development of tools and
therapies.
To register for news alerts by email go
to https://aptamergroup.com/investors/investor-news-email-alerts/.